(Q36674048)

15 August 2017

Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial (English)

1 reference

adult soft tissue sarcoma

15 August 2017

1 reference

1 reference

T Brodowicz

1

1 reference

15 August 2017

E Schwameis

2

1 reference

15 August 2017

J Widder

3

1 reference

15 August 2017

G Amann

4

1 reference

15 August 2017

C Wiltschke

5

1 reference

15 August 2017

M Dominkus

6

1 reference

15 August 2017

R Windhager

7

1 reference

15 August 2017

P Ritschl

8

1 reference

15 August 2017

R Pötter

9

1 reference

15 August 2017

R Kotz

10

1 reference

15 August 2017

C C Zielinski

11

1 reference

15 August 2017

1 January 2000

1 reference

15 August 2017

1 reference

15 August 2017

4

1 reference

15 August 2017

4

1 reference

15 August 2017

151-160

1 reference

Creative Commons Attribution 3.0 Unported

15 August 2017

start time

1 January 2000

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Adjuvant chemotherapy in the treatment of soft-tissue sarcoma.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Chemotherapy of advanced soft-tissue sarcomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

The George Edelstyn memorial lecture: radiation in the management of malignant soft tissue tumours

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Adjuvant therapy for sarcomas

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Dose response evaluation of adriamycin in human neoplasia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Surgical margin in soft tissue sarcoma. The Scandinavian Sarcoma Group experience

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

Soft tissue sarcoma. Epidemiology and prognosis in 508 patients.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395444

High dose therapy in germ cell tumors: when, what, and how much?

20 September 2018

1 reference

12 December 2020

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

12 December 2020

Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group

1 reference

12 December 2020

Treatment of the patient with stage M0 soft tissue sarcoma

1 reference

12 December 2020

Dose-response is alive and well

1 reference

12 December 2020

A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study

1 reference

12 December 2020

Randomized study of systemic chemotherapy following complete excision of nonosseous sarcomas

1 reference

12 December 2020

Dose: a critical factor in cancer chemotherapy

1 reference

12 December 2020

Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial

1 reference

12 December 2020

Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcom

1 reference

12 December 2020

Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the

1 reference

12 December 2020

Identifiers

DOI

10.1155/2000/126837

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18521295

1 reference